The Hygiology Post is presenting information about a company that seems to have much potential to help many people. 2012 may be a pivotal year in determining how helpful the patented technologies may actually be for people.
Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; obtained on 7-17-12). As a matter of disclosure : The author continues to be a current shareholder in the company.
The Senesco Technologies web site ( https://www.senesco.com/inflammation.htm; obtained on 7-17-12) has posted relevant information about its research on cancer. Here is an excerpt:
“…Senesco has shown that small inhibitory RNAs (siRNAs) that modulate eIF5A expression have the ability to downregulate the NF-kB pathway and the production of inflammatory cytokines. We have demonstrated that the siRNA can protect cells from premature death in models of diabetes and lung inflammation.
Consequently we believe that our technology could be applicable to certain inflammatory diseases.
When eIF5A siRNA was delivered intransally to mice that had been treated with LPS, TNFa and IL1a levels were both reduced by more than 95% in the lungs. In another LPS challenge experiment eIF5A siRNA pre-treated mice had significantly reduced blood levels of multiple pro-inflammatory cytokines, including TNFa and interleukins 1, 2, 6, 12, MIP-1a, and IFN-g. Importantly cytokine IL10, a down-regulator of pro-inflammatory cytokines, was unaffected.
A significant increase in the survival of insulin-producing pancreatic islet cells was achieved when mice received eIF5A1 siRNA. Concurrently, it was shown that the death of islet cells, resulting from exposure to IL-1b and IFN-g, was significantly reduced.”
The Hygiology Post welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2012 The Hygiology Post